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Abstract 
BACKGROUD & AIMS: Patients with autoimmune hepatitis (AIH) initially respond 
to corticosteroids but often relapse after treatment is withdrawn. BALB/c mice with 
disruption of programmed cell death-1 (PD-1-/- mice) given thymectomies 3 days after 
birth develop a dysregulated immne system, greatly reduced Foxp3+ regulatory T cells, 
and undergo fulminant hepatic failure resembling acute-onset AIH in humans. We 
examined whether splenectomy overcomes corticosteroid insufficiency and reduces the 
severity of AIH in these mice. We also developed a mouse model of chronic AIH to 
investigate the effects of splenectomy. 
METHODS: After thymectomy, BALB/c-PD-1-/- mice were given dexamethasone 
before or after induction of AIH; splenectomies were performed in mice that had and 
had not been given dexamethasone. Neonatal C57BL/6-PD-1-/- mice were given 
thymectomies to create a model of chronic AIH.  
RESULTS: Injection of dexamethasone before or after induction of AIH prevented 
development of fatal AIH in BALB/c-PD-1-/- mice. However, injection after AIH 
induction did not suppress splenic production of follicular helper T cells, and 
discontinuing dexamethasone led to relapse of AIH. However, splenectomy, even 
without dexamethasone, prevented AIH. Neonatal C57BL/6-PD-1-/- mice given 
thymectomies developed chronic hepatitis with fibrosis, and hyper-γ-globulinemia and 
produced anti-nuclear antibodies; AIH was found to be induced in the spleen. 
Splenectomy reduced liver inflammation in these mice and in BALB/c-PD-1-/- mice 
with AIH. 
CONCLUSIONS: Disruption of PD-1 and thymectomy, a model of AIH, cause the 
same disruptions in immune regulation but produce different phenotypes in BALB/c vs 
C57BL/6 mice. Splenectomy overcomes corticosteroid insufficiency in the mice and 
prolongs the effects of dexamethasone. 
Keywords: autoimmunity, ANA, necrosis, T cell response, Treg 
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Introduction 
 Corticosteroid administration is the first-line therapy for patients with 
autoimmune hepatitis (AIH). The majority initially respond well to corticosteroids, 
alone or in combination with azathioprine.1-4 After initial remission, maintenance 
therapy is continued for years. However, long-term treatment is discontinued in 13% of 
AIH patients because of drug-related side effects.5,6 Half of AIH patients with remission 
relapse within 6 months after corticosteroid withdrawal, and multiple relapses are 
associated with a poor prognosis.7,8 Even when liver inflammation disappears 
completely, 13% of those patients eventually relapse.9 In addition to the difficulty in 
sustaining remission, a recent study showed that the long-term mortality of AIH patients 
due to liver disease is greater than that of the general population.10 Notably, in Europe 
and the United States, AIH patients account for 4% of liver transplants.4 To find clues to 
overcoming the therapeutic insufficiency of corticosteroids, preclinical animal models 
for detail examination are needed. 
 AIH is characterized by mononuclear-cell infiltration in the liver and elevated 
gammaglobulins as well as by the production of a variety of characteristic 
autoantibodies (autoAbs), including anti-nuclear antibodies (ANA).1-3 Liver-infiltrating 
T cells are considered the primary disease mediators of inflammatory liver damage, and 
circulating autoAbs are diagnostic hallmarks.1-3 However, in AIH patients, clinical 
manifestations are varied, ranging from non-symptomatic mild chronic hepatitis to 
fulminant hepatic failure.1-3 It is unclear whether the varied clinical manifestations of 
AIH result from the same immune dysregulation. 
 Recently, we developed the first mouse model of spontaneous AIH.11,12 In 
programmed cell death 1-deficient (PD-1-/-) mice on the BALB/c background with 
neonatal thymectomy (NTx) three days after birth, immune dysregulation by a 
concurrent loss of naturally arising Foxp3+ regulatory T cells (Tregs) and 
PD-1-mediated signaling induced fatal AIH resembling acute-onset AIH, presenting in 
humans as fulminant hepatic failure.11 The development of fatal AIH was initiated at 
two weeks of age, and extensive destruction of the liver parenchyma resulted in most 
mice dying by four weeks. Fatal AIH in BALB/c-NTx-PD-1-/- mice was characterized 
by CD4+ and CD8+ T-cell infiltration with massive lobular necrosis in the liver, 
hyper-gammaglobulinemia, and production of ANA.11,12 In BALB/c-NTx-PD-1-/- mice, 
fatal AIH was initiated at two weeks by splenic follicular helper T (TFH) cells, 
powerfully assisting B cells in forming germinal centers (GCs).13  In addition, these TFH 
cells in the spleen directly migrated into the liver via the CCR6-CCL20 axis, triggering 
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the induction of AIH.12
 In the present study, using our mouse model of fatal AIH, we examined the 
effects of administering dexamethasone (DEX) versus splenectomy on the development 
or progression of AIH. In addition, we developed a new model of chronic AIH. 
NTx-PD-1-/- mice on the different genetic background C57BL/6 developed chronic 
hepatitis with fibrosis, hyper-gammaglobulinemia, and the production of ANA, 
allowing us to examine the effects of administering DEX versus splenectomy. 
 However, the development of mouse models of chronic hepatitis 
similar to the human disease remained an important challenge. 
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Materials and Methods 
 All protocols for mice, administration of DEX in vivo, histological and 
immunohistological analysis, flow cytometry analysis, isolation of lymphocytes, ELISA, 




 The data are presented as the mean values ± SD. Statistical analysis was 
performed by Student’s t-test for unpaired data to compare the values between the two 
groups, and variance was analyzed with the Tukey-Kramer test for multiple 
comparisons. Survival rates were estimated by the Kaplan-Meier method and compared 
with the log-rank test. P-values below .05 were considered significant. 
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Results 
 DEX prevents the development of fatal AIH in BALB/c-NTx-PD-1-/- mice 
 First, to determine whether corticosteroid treatment prevents AIH in 
BALB/c-NTx-PD-1-/- mice, these mice at one day after thymectomy were 
intraperitoneally injected every other day with DEX diluted in PBS or with PBS alone 
(Figure 1A). After 13 injections, mice at four weeks of age showed that DEX injections 
suppressed severe infiltration of mononuclear cells as well as massive destruction of the 
liver parenchyma with decreased serum concentrations of aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT), resulting in a significantly higher survival 
rate compared with control PBS injections (Figure 1A, B and Supplementary Figure 1A). 
These data indicate that DEX prevents fatal AIH in these mice. 
 
 Therapeutic administration of DEX induces regression of inflammation in 
the liver and significantly increases survival in BALB/c-NTx-PD-1-/- mice 
 Next, we examined whether corticosteroids might have the same therapeutic 
efficacy for AIH in BALB/c-NTx-PD-1-/- mice as for human AIH. Because AIH 
induction was started by 14 days of age in most of the mice,11,12 intraperitoneal 
injections of DEX were started at 17 days (Figure 1C). After 6 injections every other 
day, at four weeks therapeutic injections of DEX suppressed AIH, inducing 
significantly greater survival (Figure 1C, D and Supplementary Figure 1B). These data 
suggest that similar to human AIH, treatment with corticosteroids after AIH induction is 
therapeutic for BALB/c-NTx-PD-1-/- mice. 
 
 Administration of DEX reduces serum IgG levels and ANA production in 
BALB/c-NTx-PD-1-/- mice 
  Using ELISA and immunofluorescence assay, we next examined whether 
IgG or ANA levels were affected by preventive or therapeutic injections of DEX. 
Although serum IgM levels were not changed by DEX treatments, serum IgG levels 
were significantly reduced by both preventive and therapeutic injections of DEX 
(Figures 1E). These data are consistent with the finding in AIH patients, in which 
reduced serum AST after corticosteroid therapy is generally associated with reduced 
levels of γ-globulin and of IgG. In addition, ANA levels were reduced significantly in 
mice with preventive injections and slightly but not significantly in mice receiving 
therapeutic injections of DEX (Figures 1E and 1F). 
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 Therapeutic administration of DEX reduces the size of the spleen but does 
not completely regress GC-forming B cell follicles and TFH cells in the spleen of 
BALB/c-NTx-PD-1-/- mice 
 As reported previously,12 the spleens of BALB/c-NTx-PD-1-/- mice at 4 weeks 
of age were enlarged, showing multiple PNA+ GC-forming B cell follicles. DEX 
treatments significantly reduced spleen size and weight, suggesting that they affect the 
induction site of AIH development (Figures 2A, and Supplementary Figure 2A and 2B). 
However, therapeutic but not preventive DEX injections allowed persistence of multiple 
B-cell follicles in the spleen (Figure 2B upper panels) and of CD4+ TFH cells as well as 
PNA+ GC formation in the B220+ B-cell follicles (Figure 2B middle and lower panels) 
in the spleens of BALB/c-NTx-PD-1-/- mice aged 4 weeks. In addition, flow cytometric 
analysis of splenic CD4+ T cells demonstrated that these cells in mice therapeutically 
treated with DEX contained ICOS+CXCR5+ TFH cells at levels similar to controlled 
mice treated with PBS. In contrast, ICOS+CXCR5+ TFH cells in CD4+ T-cell 
populations were reduced in mice preventively treated with DEX (Figure 2C). Although 
DEX injections may affect immune cells other than T cells in the spleen, therapeutic 
injections of DEX allowed TFH cells to persist. 
 Corticosteroids directly induce apoptosis of lymphocytes, whereas Tregs 
expressing higher levels of glucocorticoid receptors are reported to be resistant to 
DEX-mediated apoptosis, probably due to high expression of Bcl-2.15-17 We next 
examined whether splenic CD4+ T cells containing TFH cells are more resistant to 
DEX-mediated apoptosis than other T cells. CD4+ and CD8+ T cells were purified from 
the spleen of BALB/c-NTx-PD-1-/- mice therapeutically treated with DEX and cultured 
with various concentrations of DEX (Figure 2D). After three days of culture, 7-AAD- 
non-apoptotic cells were significantly and dose-dependently reduced in the CD8+ T-cell 
population cultured with DEX. In contrast, 7-AAD- non-apoptotic cells were not altered 
in the CD4+ T-cell population cultured with DEX (Figure 2D). These data suggest that 
in BALB/c-NTx-PD-1-/- mice, splenic CD4+ T cells containing TFH cells are more 
resistant to DEX-mediated apoptosis than effector CD8+ T cells. 
 
 Residual splenic CD4+ cells after therapeutic injections of DEX can induce 
hepatitis in RAG2-/- mice. 
 Next, we investigated whether residual splenic CD4+ cells after therapeutic 
DEX injections can induce AIH. Total splenocytes, purified splenic CD4+ cells, or 
CD4+ T-cell depleted splenocytes were transferred from BALB/c-NTx-PD-1-/- mice 
therapeutically treated with DEX at three weeks into T- and B-cell-deficient 
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BALB/c-RAG2-/- mice. Three weeks later, we found that transferring total splenocytes 
from mice therapeutically treated with DEX induced mononuclear cell infiltrations in 
the liver of recipient mice and significantly increased serum levels of AST and ALT to 
levels similar to untreated mice (Figure 2E and Supplementary Figure 2C). Notably, 
purified splenic CD4+ T cells but not CD4+ T-cell–depleted splenocytes also induced 
hepatitis (Figure 2F and Supplementary Figure 2D). Taken together, these data suggest 
that residual splenic CD4+ cells after DEX injection trigger the recurrence of AIH in 
mice. 
 
 Ending DEX therapy induces fatal hepatitis, whereas extending it allows 
residual GC-forming B cell follicles in the spleen of BALB/c-NTx-PD-1-/- mice 
 To examine whether stopping DEX injections results in relapse, DEX 
administration was ended at 28 days of age after 6 therapeutic injections, or continued 
until 40 days of age in control mice (Figure 3A). Continuous DEX treatment maintained 
suppressed inflammatory infiltration in the liver and hepatic damage in association with 
a high survival rate (Figure 3A, 3B and Supplementary Figure 3), but GC-forming B cell 
follicles were still present in the spleens (Figure 3B). In contrast, stopping DEX at 28 
days resulted in the recurrence of hepatitis at 40 days, accompanied by reduced survival 
rates (Figure 3A, 3B, and Supplementary Figure 3). These data suggest a limitation in 
the therapeutic use of corticosteroids for resolving the dysregulation of TFH cells in the 
spleen, the AIH-induction site, in BALB/c-NTx-PD-1-/- mice. 
 
 Splenectomy after the development of AIH suppresses progression to fatal 
AIH in BALB/c-NTx-PD-1-/- mice 
 Previously we reported that neonatal splenectomy has a preventive effect on 
AIH development in BALB/c-NTx-PD-1-/- mice.12 In this study, we evaluated 
splenectomy as a therapeutic option. Similar to the neonatal procedure, splenectomy at 
7 or 10 days of age before AIH induction suppressed the development of fatal hepatitis 
(Figure 3C). Importantly, we found that splenectomy at 17 or 21 days of age after AIH 
development also suppressed liver inflammation and improved survival, sustaining 
remission until 45 days (Figure 3C-E). 
 In addition, splenectomy at 21 days of age following DEX therapy suppressed 
liver inflammation in association with a high survival rate at 40 days of age, sustaining 
remission until 60 days (Figure 3F). Moreover, when we performed splenectomy at four 
weeks of age following DEX therapy, liver inflammation was suppressed at 56 days of 
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age (Supplementary Figure 4). These data suggest that splenectomy induces prolonged 
remission of AIH in BALB/c-NTx-PD-1-/- mice. 
 
 AIH developed in C57BL/6-NTx-PD-1-/- mice shares characteristic 
components of chronic hepatitis in AIH patients 
 In AIH patients, clinical manifestations of AIH are varied, and the disease 
manifestation has been associated with specific alleles of the major histocompatibility 
complex.1-3, 18, 19 To test whether different genetic backgrounds induce milder disease 
manifestation in NTx-PD-1-/- mice, we performed NTx in PD-1-/- mice that had been 
backcrossed onto the C57BL/6 background for 11 generations.20 
 In two-week-old BALB/c-NTx-PD-1-/- mice with hepatitis, pathogenic splenic 
TFH cells were preferentially localized within B220+ B-cell follicles and autonomously 
developed PNA+ GCs (Supplementary Figure 5).12 In contrast, although in 
C57BL/6-NTx-PD-1-/- mice of the same age, splenic CD4+ T cells were located within 
the follicles, these B-cell follicles did not develop PNA+ GCs (Supplementary Figure 5 
and Figure 4A). Interestingly, flow cytometric analysis demonstrated that in parallel 
with the increase of ICOS+CD4+ T cells including CXCR5+ TFH cells in 
C57BL/6-NTx-PD-1-/- mice at 6 weeks of age (Supplementary Figure 6A), PNA+ GCs 
were autonomously developed (Figure 4A), and B220+ B cells expressed Fas and GL7 
(Figure 4B), hallmarks of GC B cells. Importantly, livers in C57BL/6-NTx-PD-1-/- mice 
as young as 4 weeks showed mononuclear cell infiltrations, predominantly in the portal 
area. The infiltration was sustained in older mice, resulting in bridging fibrosis (Figure 
4C, 4D vii, viii, and Supplementary Figure 6B). Histological examination of the liver in 
eight-week-old C57BL/6-NTx-PD-1-/- mice showed interface hepatitis with periportal 
necrosis without bile duct destruction (Figure 4D i-iii), intralobular degeneration 
(Figure 4D iv), or portal inflammation (Figure 4D v), as well as fibrosis (Figure 4D vi). 
These findings are associated with an increased HAI score and increased serum levels 
of AST and ALT (Figure 4E and Supplementary Figure 6C ). 
 In addition, C57BL/6-NTx-PD-1-/- mice older than 4 weeks showed 
hyper-gammaglobulinemia and significantly increased production of ANAs as detected 
by ELISA and immunofluorescence assay (Figure 5A-C). All C57BL/6-NTx-PD-1-/- 
mice older than 8 weeks developed AIH, whereas some of the AIH-bearing mice, to a 
lesser frequency, manifested other organ-specific autoimmunity such as sialadenitis, as 
do patients with chronic AIH (Figure 5D and Supplementary Table 1).1-3 These data 
suggest that human chronic AIH and AIH developed in C57BL/6-NTx-PD-1-/- mice 
share characteristic components of the disease. 
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 Chronic hepatitis developed in C57BL/6-NTx-PD-1-/- mice is organ-specific 
autoimmunity induced by CD4+ T cells. 
 In six-week-old C57BL/6-NTx-PD-1-/- mice, flow cytometric analysis 
demonstrated that CD3+ T cells predominantly infiltrated the liver. These cells were 
mainly CD8+ T cells and, to a lesser extent, CD4+ T cells, as described for 
BALB/c-NTx-PD-1-/- mice (Figure 5E and 5F).11 These results were further confirmed 
by immunohistology (Figure 6A). In BALB/c-NTx-PD-1-/- mice, CD4+ T cells in the 
enlarged spleen directly triggered AIH development.12 Although adult 
C57BL/6-NTx-PD-1-/- mice did not show obvious splenomegaly (Figure 6B and 
Supplementary Figure 7), transfer of splenic CD4+ T cells from AIH-bearing 
C57BL/6-NTx-PD-1-/- mice at eight weeks of age into T- and B-cell–deficient RAG2-/- 
mice induced hepatitis in recipient mice at three weeks after transfer (Figure 6C). These 
data suggest that splenic CD4+ T cells directly trigger AIH in this chronic model. 
 In addition, using ELISA sets for cytokines, we found that serum cytokine 
levels of TNF-α but not IFN-γ increased in six-week-old C57BL/6-NTx-PD-1-/- mice 
(Figure 6D). Furthermore, when we transferred splenic CD4+ T cells from AIH-bearing 
C57BL/6-NTx-PD-1-/- mice as described above (Figure 6C), transferred CD4+ T cells 
induced not only hepatitis but also elevated serum levels of TNF-α in recipient mice 
(Figure 6E). Because TNF-α directly and indirectly induces cell death of hepatocytes,21 
TNF-α may be involved in hepatocytic damage in C57BL/6-NTx-PD-1-/- mice. 
 Analysis of the TCR repertoire in several autoimmune diseases has shown 
antigen-driven clonal expansion of autoreactive T cells in the target organs.22-26 In 
patients with AIH, analyses of the TCR repertoire have shown skewing of Vβ chain 
usage, suggesting oligoclonal expansion of liver-infiltrating T cells.27, 28 In addition, 
liver-infiltrating LKM-1-specific CD4+ T cell clones have shown a restricted TCR Vβ 
repertoire.29 To determine the clonality of infiltrating CD4+ T cells in the liver, we used 
flow cytometry to examine the TCR Vβ usage of hepatic CD4+ T cells. Broad TCR Vβ 
usages were equivalent to hepatic CD4+ T cells in wild type mice and PD-1-/- mice 
without NTx (Figure 6F upper and middle panels). In contrast, in six-week-old 
C57BL/6-NTx-PD-1-/- mice, effector T cells infiltrated into the liver showed clonal 
expansion (Figure 6F lower left). Interestingly, in the case of fatal hepatitis in 
three-week-old BALB/c-NTx-PD-1-/- mice, effector T cells infiltrated into the liver 
showed more abundant clonal expansion, probably affecting severity of inflammation 
(Figure 6F lower right). These data suggest that mono- or origo-clonal expansion of 
infiltrating effector CD4+ T cells in the liver may be relevant to the proliferation of 
Maruoka et al.                                                         
11 
autoreactive CD4+ T cells induced by autoantigen-presenting dendritic cells in the 
spleen. 
 In addition, in C57BL/6-NTx-PD-1-/- mice, we found that infiltrates in the 
liver were less likely to contain Tregs (Supplementary Figure 8A). Previously, we 
demonstrated that in BALB/c-NTx-PD-1-/- mice, the transfer of Tregs could not 
suppress progression of fatal hepatitis after the induction of AIH.11 However, when 
Tregs isolated from splenocytes of adult C57BL/6-PD-1-/- mice (Supplementary Figure 
8B) were transferred into four-week-old C57BL/6-NTx-PD-1-/- mice, the transfer 
suppressed chronic AIH (Supplementary Figure 8C-E). In humans, Tregs in peripheral 
blood have the same suppressive activity as Tregs isolated from the spleen in mice. 30-32 
Thus, Tregs isolated from peripheral blood and expanded ex vivo might be able to 
suppress human AIH. 
 
 The spleen is the induction site of AIH in C57BL/6-NTx-PD-1-/- mice, and 
splenectomy suppresses chronic AIH similar to fulminant AIH. 
 C57BL/6-NTx-PD-1-/- mice at 4 weeks showed mononuclear cell infiltrations 
in the liver and increased serum levels of AST and ALT (Figure 4C and 7A). To 
examine whether corticosteroids have therapeutic efficacy for chronic AIH in 
C57BL/6-NTx-PD-1-/- mice as in human AIH, intraperitoneal injections of DEX were 
started at 4 weeks (Figure 7B). After 14 injections every other day until eight weeks of 
age, therapeutic injections of DEX suppressed AIH (Figure 7B and Supplementary 
Figure 9). 
 As in BALB/c-NTx-PD-1-/- mice, neonatal splenectomy also suppressed AIH 
in C57BL/6-NTx-PD-1-/- mice (Figure 7C, Supplementary Figure 10A and 10B), 
suggesting that the spleen is the induction site for chronic AIH development in 
C57BL/6-NTx-PD-1-/- mice. 
 Finally, we evaluated splenectomy as a therapeutic option, performing 
splenectomies on four-week-old mice. Similar to the neonatal procedure, splenectomy 
at four weeks suppressed AIH in eight-week-old C57BL/6-NTx-PD-1-/- mice (Figure 
7D, Supplementary Figure 10C and 10D). Notably, splenectomy neither induced fatal 
infection nor decreased the survival rate (Supplementary Table 2), whereas splenectomy 
at 12 weeks suppressed AIH, sustaining remission until 20 weeks of age (Figure 7E and 
7F). Thus, these data suggest that splenectomy has therapeutic efficacy for chronic AIH 
similar to fulminant AIH.
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Discussion 
  Using the AIH models, we here examined the effects of administering 
dexamethasone (DEX) to find clues to overcoming therapeutic insufficiency of 
corticosteroids for AIH. We demonstrated that TFH cells in the spleen are responsible 
not only for the development of AIH but also for relapse after corticosteroid treatment. 
In BALB/c-NTx-PD-1-/- mice, the spleen is the induction site for fatal AIH, and 
responsible TFH cells are dysregulated in the spleen under the concurrent loss of Tregs 
and PD-1-mediated signaling. CCR6-CCL20 axis-dependent migration of these T cells 
triggers AIH.12 In addition, fatal progression is mediated by further differentiation of 
Th1-type effector T cells from TFH cells in the spleen, and a specific 
chemokine-dependent migration of those T cells is crucial for fatal progression 
(unpublished data). We demonstrated that injections of DEX are therapeutic for fatal 
AIH in this model, whereas TFH cells still exist in the spleen, even after continuous 
DEX administration: stopping the treatment resulted in fatal AIH. In addition, residual 
splenic CD4+ T cells after therapeutic injections of DEX were more resistant to 
DEX-mediated apoptosis, and transfer of these residual splenic CD4+ cells induced the 
development of hepatitis in the recipient RAG2-/- mice. From these data, we concluded 
that in the mouse model of AIH, corticosteroid treatment has the drawback of allowing 
dysregulated TFH cells to remain in the spleen.  
 We described another AIH model in which C57BL/6-NTx-PD-1-/- mice 
developed chronic hepatitis with fibrosis, hyper-gammaglobulinemia, and the 
production of ANA. Notably, dysregulated TFH cells were generated in the spleen, 
neonatal splenectomy suppressed chronic AIH, and transfer of splenic CD4+ T cells 
induced hepatitis in the recipient RAG2-/- mice. These results indicate that in mice, the 
same induction mechanisms are involved in AIH development, with manifestations 
ranging from acute onset to chronic. In humans, it is unknown at present whether the 
spleen is the induction site of AIH or whether TFH cells are responsible for the 
development of AIH, though splenomegaly is a common clinical finding in patients 
with active AIH.1-3 Therefore, it is important to know whether similar mechanisms are 
involved in the relapse of human AIH after corticosteroid withdrawal. 
  In our previous and present studies, we showed that splenectomy, either 
neonatal or at 7 or 10 days of age before the induction of AIH, suppressed AIH 
presenting as fulminant hepatic failure in BALB/c-NTx-PD-1-/- mice.12 In this study, we 
revealed that neonatal splenectomy also suppressed the development of chronic AIH in 
C57BL/6-NTx-PD-1-/- mice. Because patients with severe AIH have a high potential for 
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recurrence after liver transplantation, leading to a greater probability of graft loss, 
splenectomy might well prevent such recurrence. 
 Interestingly, we further observed in this study that splenectomy after the 
development of AIH suppressed liver inflammation with manifestations ranging from 
acute onset to chronic. In the acute AIH model, splenectomy alone suppressed liver 
inflammation and sustained remission for 4 weeks. In addition, splenectomy following 
DEX therapy suppressed AIH and extended remission beyond 4 weeks. Moreover, in 
the chronic AIH model, splenectomy at 12 weeks of age suppressed AIH, sustaining 
remission until 20 weeks. It is well known that AIH patients in remission after 
withdrawal of corticosteroids are likely to relapse and that multiple relapses are 
associated with poor prognosis.7, 8 Therefore, it is of interest to determine whether, in 
some patients with AIH, splenectomy might be considered though this will need to be 
very carefully assessed given the concerns related to splenectomy. 
 In conclusion, we demonstrated that although corticosteroid treatment has 
therapeutic efficacy for AIH in mice, it allows residual splenic dysregulated TFH cells to 
remain after the treatment, which appear to be responsible for relapse. In addition, we 
found that splenectomy overcomes this insufficiency, inducing prolonged remission of 
AIH. These data may prove useful in obtaining complete remission in human AIH. 
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Either preventive or therapeutic injection of dexamethasone (DEX) suppresses 
fatal AIH in BALB/c-NTx-PD-1-/- mice. In prevention, mice at one day after 
thymectomy were intraperitoneally injected every other day with 1.0 mg/kg of 
DEX diluted in PBS (n=5) or PBS alone (n=17). After 13 injections, mice at four 
weeks of age were sacrificed (A, B, E, F). In therapeutic injections, mice at 14 
days after thymectomy were injected every other day with DEX (n=11) or PBS 
alone (n=13). After 6 injections, mice at four weeks of age were sacrificed (C-F). 
Survival rate (A, C). Liver stainings for hematoxylin and eosin (B, D). Serum 
levels of IgM, IgG and ANA measured by ELISA (E). Serum titers of ANAs. Open 
circles indicate the maximum dilution of sera from individual mice as detected by 
fluorescence immunohistology (F). Bars indicate the mean of each group, and 
the error bars indicate SD. Asterisks indicate P <0.05. All scale bars, 100 µm. 
 
Figure 2 
Therapeutic administration of DEX reduces spleen weight but does not 
completely regress TFH cells in the spleen of BALB/c-NTx-PD-1-/- mice. Mice 
were injected with DEX or PBS alone preventively or therapeutically, as 
described in Fig. 1. (A) Spleen weights. (B) Histological analysis of the spleens 
from each group. Stainings for hematoxylin and eosin. Arrowheads indicate 
follicles. Spleens from each group were immunohistologically stained for CD4, 
PNA (green), and B220 (red). (C) Flow cytometric analysis of splenic CD4+ T 
cells from each group. Numbers in plots indicate percentage of ICOS+CXCR5+ 
and ICOS+CXCR5- cells in the CD4+ T-cell population (left panels). Numbers of 
ICOS+CXCR5+ CD4+ T (TFH) cells were calculated by (percentage of the cells in 
viable cells) x (No. of viable cells) (right panel). (D) Flow cytometric analysis of 
CD4+ and CD8+ T cells. Spleen cells of mice injected with DEX therapeutically 
were cultured for three days with anti-CD3, anti-CD28 mAbs, and the indicated 
concentration of DEX. Percentages of 7-AAD- cells in CD3+CD4+ and CD3+CD8+ 
T cells are shown. Data represent one of three separate experiments. (E, F) 
Stainings for hematoxylin and eosin of the livers from recipient BALB/c-RAG2-/- 
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mice at three weeks after transfer. Total splenocytes were isolated and 
intravenously transferred from BALB/c-NTx-PD-1-/- mice with or without 
therapeutic injections of DEX (E). Purified splenic CD4+ T cells or CD4+ T-cell 
depleted splenocytes (CD4- cells) were transferred from BALB/c-NTx-PD-1-/- 
mice therapeutically treated with DEX (F). Bars indicate the mean of each group, 
and the error bars indicate SD. Asterisks indicate P <0.05. n. s., not significant. 
Scale bars, 100 µm. 
 
Figure 3 
Splenectomy overcomes therapeutic insufficiency of corticosteroids and induces 
prolonged remission of AIH in BALB/c-NTx-PD-1-/- mice. (A, B) Mice were 
injected with DEX therapeutically, as described in Fig. 1. Mice with DEX injection 
extended until 40 days of age (Extension, n=7) or mice with cessation of DEX 
injections at 4 weeks of age (Cessation, n=10) were sacrificed at 40 days. 
Survival rate of each group (A). Stainings of the liver and spleen for hematoxylin 
and eosin (B). (C and D) Splenectomy (Splx) was performed on 
BALB/c-NTx-PD-1-/- mice at 7 (n=6) or 10 days (n=5) before the induction and 17 
(n=6) or 21 days of age (n=6) after the development of AIH. Survival rate of each 
group (C) and liver stainings for hematoxylin and eosin at 28 days of age (D). (E) 
Survival rate at 45 days of age in BALB/c-NTx-PD-1-/- mice undergoing 
splenectomy (Splx, n=8) or sham operation (Sham, n=8) at 17 days of age. (F) 
Mice were injected with DEX therapeutically, as described in Fig. 1. After 3 
injections, mice stopped receiving DEX injections and underwent splenectomy 
(Splx, n=6) or sham operation (n=5) at 21 days of age. Survival rate of each 
group (left panel). Splx mice were sacrificed at 40 days of age, and the livers 
were harvested. Liver stainings for hematoxylin and eosin are shown in the 
middle panel. For the experiment in Fig. 3F right panel, indicated mice were 
sacrificed at 60 days (n=3). Asterisks indicate P <0.05. All scale bars, 100 µm. 
 
Figure 4 
Adult C57BL/6-NTx-PD-1-/- mice spontaneously develop B220+PNA+ germinal 
centers (GCs) with CD4+ TFH cells in the spleen and suffer chronic hepatitis with 
fibrosis. (A) Immunohistological staining of spleens in indicated mice at two to 
twelve weeks. The spleens were stained for CD4, CD8, PNA (green) and B220 
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(red). (B) Flow cytometric analysis of splenic B cells in indicated mice. Numbers 
in plots indicate percent of B220+Fas+GL7+ GC B cells. (C) Liver stainings for 
hematoxylin and eosin for C57BL/6-NTx-PD-1-/- mice at two to twelve weeks. (D) 
Liver stainings for hematoxylin and eosin for 8-week-old (i-v of left panels) and 
48-week-old mice (HE, right panels). Masson’s trichrome stainings of livers in 
8-week-old (vi of left panels) and 48-week-old mice (MT, right panels). (E) 
Serum levels of AST and ALT in C57BL/6-PD-1-/- mice at indicated ages with 
(closed circles) or without NTx (open circles). Bars indicate the mean of each 
group, and the error bars indicate SD. Asterisks indicate P <0.05. n.s., not 
significant. All scale bars, 100 µm. 
 
Figure 5 
Adult C57BL/6-NTx-PD-1-/- mice develop hyper-gammaglobulinemia, ANA 
production as well as autoimmunity in other organs, and T cells are 
predominantly infiltrated in the inflamed liver. (A and B) The serum levels of total  
immunoglobulin (Ig) subclasses (A) and ANA subclasses (B) determined by 
ELISA. Data shown are from C57BL/6-PD-1-/- mice at indicated ages with 
(closed bars) or without NTx (open bars). Bars indicate the mean of each group, 
and the error bars indicate SD. Asterisks indicate P <0.05. N.D., not detected. 
n.s., not significant. (C) Autoantibodies detected by fluorescence 
immunohistology as described in Supplementary Methods. Sera (x100 diluted) 
from 12-week-old C57BL/6-PD-1-/- mice with or without NTx were used. Scale 
bars, 100 µm (upper and middle panels) or 10 µm (lower panel). (D) Histological 
findings of various organs from 12-week-old C57BL/6-NTx-PD-1-/- mice. Scale 
bars, 100 µm. (E) Cell numbers of each subset of liver mononuclear cells as 
described in Supplementary Methods. Data represent the numbers in the 
indicated mice at 6 weeks of age. (F) Flow cytometric analysis (left panel) and 
cell numbers (right panel) of CD3+CD4+ and CD3+CD8+ T cells in the liver of 
6-week-old C57BL/6-PD-1-/- mice with or without NTx. Numbers in quadrants 
indicate percentage of cells in that gate (left panel). Data shown in Fig. 5C, E 
and F are from one of three separate experiments. 
 
Figure 6 
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Splenic CD4+ T cells are responsible for induction of chronic AIH, and CD4+ T 
cells infiltrated in the liver show clonal expansion in NTx-PD-1-/- mice. (A) 
Immunohistological staining of livers. The livers in 6-week-old C57BL/6-PD-1-/- 
mice with or without NTx were stained with FITC-anti-CD4 or -anti-CD8. The 
insets show stainings for CD4 or CD8 with a higher magnification. Scale bars, 
100 µm. (B) Macroscopic view of the liver, spleen, and mesenteric lymph node 
(MLN) from 12-week-old indicated mice. Scale bars, 1 cm. (C) Purified 
CD3+CD4+ T cells from the spleen of 8-week-old C57BL/6-PD-1-/- mice with or 
without NTx were transferred into RAG2-/- mice intravenously. Three weeks after 
transfer, recipient mice were examined. Liver stainings for hematoxylin and 
eosin. Scale bars, 100 µm (left panel). Serum levels of the liver transaminases, 
AST and ALT (right panel). (D) Serum levels of TNF-α and IFN-γ in 6-week-old 
indicated mice as measured by ELISA. (E) Serum levels of TNF-α in recipient 
mice transferred as described in Fig. 6C. (F) TCR Vβ  usages of hepatic CD4+ T 
cells in indicated mice assessed by flow cytometry. Mononuclear cells in the liver 
were stained as described in Supplementary Methods. Data shown are from one 
of three separate experiments. Bars in Fig. 6C-E indicate the mean of each 
group, and the error bars indicate SD. Asterisks indicate P <0.05. n.s., not 
significant. N.D., not detected. 
 
Figure 7 
C57BL/6-NTx-PD-1-/- mice at 4 weeks of age show increased serum levels of the 
liver transaminases, and therapeutic injections of DEX as well as splenectomy 
suppress chronic AIH. (A) Serum levels of the liver transaminases AST and ALT 
in four-week-old indicated mice. (B) Intraperitoneal injections of DEX (n=5) or 
PBS (n=5) were started at four weeks. After 14 injections every other day until 
eight weeks of age, mice were sacrificed and examined. (C) Mice underwent a 
splenectomy (NSplx, n=5) or a sham operation (n=5) at one day after NTx, and 
were analyzed at eight weeks. (D) Four-week-old mice underwent a 
splenectomy (Splx, n=5) or a sham operation (n=5) and were analyzed at eight 
weeks. (E and F) Twelve-week-old mice underwent a splenectomy (Splx, n=5) or 
a sham operation (n=5) and were analyzed at 20 weeks. Liver stainings for 
hematoxylin and eosin (B-E) and serum levels of AST and ALT (A and F).  Bars 
indicate the mean of each group, and the error bars indicate SD. Asterisks 
indicate P <0.05. Scale bars, 100 µm. 
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 C57BL/6 and BALB/c mice were purchased from Japan SLC (Shizuoka, 
Japan), and PD-1-/- and RAG-2-/- mice on a C57BL/6 or BALB/c background were 
generated as described.1-3 All of these mice were bred and housed under specific 
pathogen-free conditions. Thymectomy and splenectomy of the mice were performed as 
described.4-6 The sham splenectomy was performed by cutting the peritoneum without 
removing the spleen. All mouse protocols were approved by the Institute of Laboratory 
Animals, Graduate School of Medicine, Kyoto University. 
 
 Administration of dexamethasone (DEX) in vivo 
 For the preventive protocol, BALB/c–NTx−PD-1-/- mice at one day after 
thymectomy were intraperitoneally injected every other day with 1.0 mg/kg of DEX 
(Sigma-Aldrich, St. Louis, MO) diluted in phosphate-buffered saline (PBS) or PBS 
alone. After 13 injections, mice at four weeks of age were sacrificed, and the livers, 
spleens, and sera were harvested. For the therapeutic protocol, BALB/c–NTx−PD-1-/- 
mice at 14 days after thymectomy were intraperitoneally injected every other day with 
1.0 mg/kg of DEX diluted in PBS or PBS alone. In C57BL/6–NTx−PD-1-/- mice, the 
therapeutic injections of 0.5 mg/kg of DEX every other day were started at 4 weeks of 
age. After indicated injections, mice were sacrificed. 
 
 Histological and immunohistological analysis 
 Organs were fixed in neutral buffered formalin and embedded in paraffin 
wax. Sections were stained with hematoxylin and eosin or Masson’s trichrome for 
histopathology. Fluorescence immunohistology was performed on frozen sections as 
described previously4, 5 using FITC-conjugated anti-CD4 (RM4-5), anti-CD8a (Ly-2) 
(eBioscience, San Diego, CA), peanut agglutinin (PNA, Vector Laboratories, 
Burlingame, CA), biotin-labeled anti-B220 (RA3-6B2) (BD Biosciences, San Jose, 
CA) followed by Texas red-conjugated avidin (Vector Laboratories). To detect 
autoantibodies, livers were collected from wild-type BALB/c and C57BL/6 mice. 
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Sections were stained with x100 to x3200 diluted sera from indicated mice, followed 
by FITC-conjugated anti-mouse IgG (Cappel, Chester, PA). 4 
 
 Flow cytometry analysis and isolation of lymphocytes 
 Single cells from the livers and spleens were prepared as described.4, 5 The 
following monoclonal antibodies (mAbs) were used for surface staining: 
FITC-conjugated anti-CD4, anti-CXCR5 (2G8), anti-GL7, anti-CD11c (HL3) (BD 
Biosciences), anti-DX5 (eBioscience); PE-conjugated anti-CD3e (145-2C11), 
anti-ICOS, anti-Gr-1 (RB6-8C5) (eBioscience); anti-CD95/Fas (Jo2) (BD 
Biosciences); APC-Cy7-conjugated anti-CD4 (GK1.5), biotin-labeled B220 (BD 
Biosciences); and APC-conjugated streptavidin, anti-CD8a, and anti-CD25 (PC61.5), 
anti-CD11b (M1/70) (eBioscience). For flow cytometric analysis of splenic CD4+ T 
cells in Figure 2C and Supplementary Figure 6A, spleen cells were stained with 
FITC-anti-CXCR5, PE-anti-ICOS, APC-Cy7-anti-CD4. To analyze splenic B220+ B 
cells in Figure 4B, cells were stained with FITC-anti-GL7, PE-anti-CD95/Fas, and 
biotin-labeled B220 followed by APC-conjugated streptavidin. Data of flow 
cytometric analysis in Figure 5E and 5F represent cell numbers of the following cell 
subsets in the liver: CD11b+CD11c- macrophages, CD11c+ dendritic cells (DCs), 
CD11b+Gr-1+ myeloid cells, CD3-DX5+ natural killer cells (NK cells), CD3+DX5+ 
natural killer T cells (NKT cells), CD3+DX5- T cells, B220+ B cells, CD3+CD4+ T 
cells and CD3+CD8+ T cells. For the analysis of T cell receptor (TCR) Vβ usage in 
Figure 6F, cells were stained with FITC-anti-Vβ2 (B20.6), anti-Vβ3 (KJ25), anti-Vβ4 
(KT4), anti-Vβ5.1 and Vβ5.2 (MR9-4), anti-Vβ6 (RR4-7), anti-Vβ7 (TR310), 
anti-Vβ8.1 and Vβ8.2 (MR5-2), anti-Vβ8.3 (IB3.3), anti-Vβ9 (MR10-2), anti-Vβ10b 
(B21.5), anti-Vβ11 (RR3-5), anti-Vβ12 (MR11-1), anti-Vβ13 (MR12-3), anti-Vβ14 
(14-2), anti-Vβ17a (KJ23), PE-anti-CD3e, and APC-Cy7-anti-CD4 for CD4+ T cells 
by using Mouse Vβ TCR Screening Panel (BD Biosciences). Stained cells were 
analyzed with a FACSCantoTM II (BD Biosciences). Data were analyzed using Cell 
Quest ProTM (BD Biosciences). Dead cells were excluded on the basis of side- and 
forward-scatter characteristics, and viable cell numbers were calculated as follows: 
(the percentage of cells in the cell type) × (the number of viable cells). For 7-AAD 
staining in Figure 2D, single cells were isolated from the spleens of 3-week-old 
BALB/c–NTx−PD-1-/- mice injected with DEX therapeutically. Isolated spleen cells 
(1x106) were cultured with 10–1000 ng/ml of DEX under plate-bound anti-CD3 (1 
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μg/ml) and soluble anti-CD28 (5 μg/ml).  Round-bottomed 96-well culture plates 
were used with D-MEM supplemented with 10% fetal bovine serum, 50 mmol/L 
2-mercaptoethanol, 100 U/ml penicillin, and 100 µg/ml streptomycin. Three days 
after the culture, cells were harvested and stained with FITC-conjugated anti-CD3e 
(eBioscience) and 7-AAD (BD Biosciences) and either PE-Texas Red-conjugated 
anti-CD4 (Abcam, Cambridge, UK) or PE-Texas Red-conjugated anti-CD8 (Abcam). 
In Foxp3 staining, cells were fixed and permeabilized using Foxp3 staining buffer 
(eBioscience) and stained with PE-anti-Foxp3 (eBioscience). 
 
 ELISA 
 Serum immunoglobulin (Ig) levels were determined by ELISA as described,7 
and Ab sets to detect mouse IgG1, IgG2a, IgG2b, IgG3 from BD Biosciences and 
anti-mouse IgM from AbD Serotec (Oxford, UK) were used. To detect serum ANAs, 
microtiter plates (Nunc, Roskilde, Denmark) were incubated with 10 µg/ml antigens, 
and the nuclear fraction was prepared from normal liver.8 Ab sets to detect mouse ANA 
subclasses were the same as above. Serum concentrations of TNF-α and IFN-γ were 
measured with mouse cytokine ELISA sets from eBioscience according to the 
manufacturer’s protocols. 
 
 Isolation of lymphocytes and adoptive transfer 
 For transfer of total spleen cells, BALB/c–NTx−PD-1-/- mice at 14 days 
after thymectomy were intraperitoneally injected every other day with or without 1.0 
mg/kg of DEX diluted in PBS. Single cells were isolated from the spleens of 
3-week-old mice. Isolated spleen cells (1x107) were intravenously injected into 
RAG2-/- recipient mice on a BALB/c background at 4-6 weeks of age. To transfer 
CD4+ T cells or CD4+ T cell-depleted spleen cells, 3-week-old BALB/c–NTx−PD-1-/- 
mice were therapeutically injected with DEX. Cells were prepared using mouse CD4 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the 
manufacturer’s protocols. Purity was assessed by flow cytometry. CD4+ T cells were 
purified to reach >90% purity, and CD4- splenocytes reached >99% purity. Isolated 
cells (1x106) were intravenously injected into BALB/c–RAG2-/- mice at 4-6 weeks of 
age. 
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 For transfer of CD4+ T cells from C57BL/6−PD-1-/-
 
mice, CD3+CD4+ T 
cells were prepared from the spleens of 8-week-old C57BL/6−PD-1-/-
 
mice with or 
without NTx obtained by a FACS AriaTMII. Isolated CD3+CD4+ T cells (1x106) were 
intravenously injected into C57BL/6–RAG2-/- recipient mice at 4-6 weeks of age. For 
transfer, CD4+CD25+ regulatory T cells (Tregs) were purified from the spleens of 
eight-week-old C57BL/6−PD-1-/-
 
mice. Tregs were obtained by a FACS Aria TMII and 
isolated with a CD4+CD25+ T cell to reach >99% purity. Tregs (1x106) were 
intravenously injected into C57BL/6−NTx−PD-1-/- mice at 4 weeks of age. Four 
weeks post-transfer, the recipient mice at 8 weeks of age were sacrificed. 
 
 Histological activity index (HAI) score 
 Histological activity of chronic active hepatitis was assessed according to a 
semiquantitative scoring system, as described previously for humans.9 For 
histological assessment, all specimens were reviewed blind by at least two 
hepatologists. Using Knodell’s HAI scoring system, liver specimens were graded in 
four categories. Category I, periportal and/or bridging hepatocellular necrosis was 
graded from 0 to 10, where 0=none, 1=mild piecemeal necrosis, 3=moderate 
piecemeal necrosis (involves less than 50% of the circumference of most portal tracts), 
4=marked piecemeal necrosis (involves more than 50% of the circumference of most 
portal tracts), 5=moderate piecemeal necrosis plus bridging necrosis, 6=marked 
piecemeal necrosis plus bridging necrosis, 10=multilobular necrosis. Category II, 
intralobular degeneration and focal hepatocellular necrosis were graded from 0 to 4, 
where 0=none, 1=mild (acidophilic bodies, ballooning degeneration and/or scattered 
foci of hepatocellular necrosis in <1/3 of lobules or nodules), 3=moderate 
(involvement of 1/3-2/3 of lobules or nodules), 4=marked (involvement of >2/3 of 
lobules or nodules). Category III, portal inflammation, was graded from 0 to 4, where 
0=no portal inflammation, 1=mild (sprinkling of inflammatory cells in <1/3 of portal 
tracts), 3=moderate (increased inflammatory cells in 1/3-2/3 of portal tracts), 
4=marked (dense packing of inflammatory cells in >2/3 of portal tracts). Category IV, 
fibrosis, was graded from 0 to 4, where 0=no fibrosis, 1=fibrous portal expansion, 
3=bridging fibrosis (portal-portal or portal-central linkage), 4=cirrhosis. 
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Supplementary Figure 1 
Either preventive or therapeutic injection of dexamethasone (DEX) suppresses 
fatal AIH in BALB/c–NTx–PD-1-/- mice. (A) BALB/c–NTx–PD-1-/- mice at one day 
after thymectomy were intraperitoneally injected every other day with 1.0 mg/kg 
of DEX diluted in PBS (n=5) or PBS alone (n=17). After 13 injections, mice at 
four weeks of age were sacrificed, and sera were harvested. Serum levels of the 
liver transaminases AST and ALT. (B) NTx–PD-1-/- mice at 14 days after 
thymectomy were intraperitoneally injected every other day with 1.0 mg/kg of 
DEX diluted in PBS (n=11) or PBS alone (n=13). After 6 injections, mice at four 
weeks of age were sacrificed. Serum levels of AST and ALT are shown. Bars 
indicate the mean of each group, and the error bars indicate SD. Asterisks 
indicate P < 0.05. 


















Supplementary Figure 2 
Therapeutic administration of DEX reduces the size of the spleen, and residual 
CD4+ T cells in the spleen of BALB/c–NTx–PD-1-/- mice can induce hepatitis. 
BALB/c–NTx–PD-1-/- mice were injected with DEX or PBS alone preventively or 
therapeutically, as described in Fig. 1. (A) Macroscopic view of spleen. (B) 
Splenic sizes. (C, D) Serum levels of the liver transaminases AST and ALT in 
recipient BALB/c–RAG2-/- mice at three weeks after transfer. Total splenocytes 
were isolated and transferred from BALB/c–NTx–PD-1-/- mice with or without 
therapeutic injections of DEX (C). Purified splenic CD4+ T cells or CD4+ T-cell 
depleted splenocytes (CD4- cells) were transferred from BALB/c–NTx–PD-1-/- 
mice therapeutically treated with DEX (D). Bars indicate the mean of each group, 
and the error bars indicate SD. Asterisks indicate P < 0.05. n. s., not significant. 
Scale bars, 1 cm. 
 









Supplementary Figure 3 
Cessation of DEX therapy induces relapse of hepatitis in BALB/c–NTx–PD-1-/- 
mice. BALB/c–NTx–PD-1-/- mice at 14 days after thymectomy were 
intraperitoneally injected every other day with 1.0 mg/kg of DEX. Mice with DEX 
injection extended until 40 days of age (Extension, n=7) or mice with cessation 
of DEX injections at 4 weeks of age (Cessation, n=10) were sacrificed at 40 days 
of age, and sera were harvested. Serum levels of the liver transaminases AST 
and ALT are shown. The bars indicate the mean of each group, and the error 









Supplementary Figure 4 
Splenectomy overcomes therapeutic insufficiency of corticosteroids and induces 
prolonged remission of AIH in BALB/c–NTx–PD-1-/- mice. BALB/c–NTx–PD-1-/- 
mice at 14 days after thymectomy were intraperitoneally injected every other day 
with 1.0 mg/kg of DEX. After 6 injections, mice stopped receiving DEX injections 
and underwent splenectomy (Splx, n=3) or sham operation (n=3) at 28 days of 
age. Mice at 56 days of age were sacrificed, and the livers were harvested. 
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Histological analysis of the liver from each group. Staining of the liver for 
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Supplementary Figure 5 
Splenic CD4+ T cells are preferentially localized within B220+ B-cell follicles in 
NTx–PD-1-/- mice at two weeks of age, whereas PNA+ germinal centers exist in 
B220+ B-cell follicles in the spleen of AIH-bearing NTx–PD-1-/- mice on the 
BALB/c background but in not those on the C57BL/6 background. 
Immunohistological staining of the spleen (left panels) and H&E (HE) staining of 
the liver (right panels). The spleens and livers were from 2-week-old PD-1+/+ 
mice or PD-1-/- mice with or without NTx on the BALB/c or C57BL/6 background. 
The spleens were stained with FITC-conjugated anti-CD4, anti-CD8 or peanut 
agglutinin (PNA) (green) and biotin-labeled anti-B220 followed by Texas 














Supplementary Figure 6 
Adult C57BL/6–NTx–PD-1-/- mice with increased numbers of splenic TFH cells 
develop chronic hepatitis. (A) Flow cytometric analysis of splenic CD4+ T cells in 
C57BL/6–PD-1-/- mice with or without NTx at indicated ages. The cells were 
stained with FITC-anti-CXCR5, PE-anti-ICOS, APC-Cy7-anti-CD4. Numbers in 
plots indicate percentage of cells in each gate in the CD4+ T-cell population. (B) 
Histological findings from the livers of 6-week-old C57BL/6–PD-1-/- mice with or 
without NTx. In contrast to mice without NTx, those with NTx showed dense 
packing of inflammatory cells marked in portal branches (black arrowhead). 
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Scale bars, 100 µm. (C) Knodell’s histological activity index (HAI) score for livers 
in 8-week-old C57BL/6–PD-1-/- mice with (n=10) or without NTx (n=10). HAI 
score is graded in four categories: I, periportal and/or bridging necrosis; II, 
intralobular degeneration and focal hepatocellular necrosis; III, portal 












Supplementary Figure 7 
Adult C57BL/6–NTx–PD-1-/- mice do not show obvious splenomegaly. Splenic 
sizes (A) and weights of the spleen, liver, and mesenteric lymph node (MLN) (B) 
in 12-week-old C57BL/6-PD-1-/- mice with or without NTx. Bars indicate the 

























Supplementary Figure 8  
Transfer of regulatory T cells (Tregs) has therapeutic efficacy for chronic AIH in 
C57BL/6–NTx–PD-1-/- mice. (A) Flow cytometric analysis of Tregs in the liver 
from the indicated mice at 6 weeks of age. The cells were stained with 
FITC-anti-CD4, PE-anti-CD3, APC-anti-CD25. Numbers of CD3+CD4+CD25+ 
Tregs were calculated by (percentage of the cells in the cell types) X (number of 
viable cells). Data shown are one of three separate experiments. (B) Flow 
cytometric analysis of CD4+CD25+ T cells in the spleen from the 8-week-old 
C57BL/6–PD-1-/- or PD-1+/+ mice. The cells were isolated from spleen and 
stained with FITC–anti-CD4, APC-anti-CD25, and PE-anti-Foxp3. Filled 
histograms represent staining of CD4+CD25+ T cells with Foxp3; open 
histograms represent the isotype control. Data represent one of five experiments. 
Numbers in histograms indicate percentages of Foxp3+ cells in a viable 
CD4+CD25+ T cells. (C-E) For Treg transfer, 1x106 of Tregs were prepared from 
8-week-old C57BL/6–PD-1-/- mice. Four-week-old C57BL/6–NTx–PD-1-/- mice 
were intravenously injected with 1x106 of Tregs (n=5) or PBS (n=5). Recipient 
mice were analyzed at 8 weeks of age. (C) Histological findings of the liver. 
Scale bars, 100 µm. (D) Serum levels of the liver transaminases, aspartate 
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aminotransferase (AST), and alanine aminotransferase (ALT). (E) Knodell’s 
histological activity index (HAI) score. Bars indicate the mean of each group, and 












Supplementary Figure 9 
Therapeutic injections of DEX suppress chronic AIH in C57BL/6–NTx–PD-1-/- 
mice. Intraperitoneal injections of DEX (n=5) or PBS (n=5) were started at 4 
weeks of age in C57BL/6–NTx–PD-1-/- mice. After 14 injections every other day 
at eight weeks of age, mice were sacrificed and examined. Serum levels of the 
liver transaminases AST and ALT are shown. Bars indicate the mean of each 



























Supplementary Figure 10 
The spleen is the induction site of chronic AIH in C57BL/6–NTx–PD-1-/- mice, 
and splenectomy suppresses chronic AIH. (A, B) C57BL/6–NTx–PD-1-/- mice 
underwent a splenectomy (NSplx, n=5) or a sham operation (n=5) at one day 
after NTx, and were analyzed at 8 weeks of age. (C, D) Four-week-old 
C57BL/6–NTx–PD-1-/- mice underwent a splenectomy (Splx, n=5) or a sham 
operation (n=5) and were analyzed at 8 weeks of age. Total HAI scores for livers 
as described in Supplementary Methods (A and C). Serum levels of the liver 
transaminase, AST and ALT (B and D). Bars indicate the mean of each group, 
and horizontal short bars indicate SD. Asterisks indicate P <0.05. n.s., not 
significant. 
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